05/05/2025 – AB Science announced that new analyses from its phase 3 trial in ALS and preclinical animal model data have been accepted for presentation at the ENCALS annual meeting (June 3-6, 2025, Turin, Italy) Download PDF Post navigationPreviousPrevious post:AB Science will publish its 2024 annual financial report on May 9, 2025Related PostsAB Science will publish its 2024 annual financial report on May 9, 2025May 1, 2025European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseApril 14, 2025Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025Summary of the webcast held on January 28, 2025January 29, 2025AB Science webcast of January 28, 2025January 29, 2025
European Medicines Agency has granted orphan drug designation in the European Union for AB8939 in the treatment of acute myeloid leukemiaApril 23, 2025
AB Science receives notice of allowance for Unites States patent covering masitinib until 2040 in the treatment of sickle cell diseaseApril 14, 2025
Article from the leading publication Life Sciences Magazine featuring AB Science’s masitinib and its Phase 3 principal investigator, the neurologist Patrick VermerschMarch 4, 2025
